戈沙妥珠单抗治疗三阴性乳腺癌的研究进展

doi:10.3760/cma.j.cn371439-20220715-00123

国际肿瘤学杂志 ›› 2022, Vol. 49 ›› Issue (10): 619-622.doi: 10.3760/cma.j.cn371439-20220715-00123

戈沙妥珠单抗治疗三阴性乳腺癌的研究进展

王孟超, 陈立伟(), 孔凡铭

天津中医药大学第一附属医院肿瘤科国家中医针灸临床医学研究中心，天津 300000

收稿日期:2022-07-15 修回日期:2022-09-11 出版日期:2022-10-08 发布日期:2022-12-01
通讯作者: 陈立伟 E-mail:iron9999@126.com
基金资助:
国家重点研发计划(2018YFC1707400)

Progress in the treatment of triple negative breast cancer with sacituzumab govitecan

Wang Mengchao, Chen Liwei(), Kong Fanming

Department of Oncology， First Affiliated Hospital of Tianjin University of Chinese Medicine， National Clinical Research Center of Chinese Acupuncture and Moxibustion， Tianjin 300000， China

Received:2022-07-15 Revised:2022-09-11 Online:2022-10-08 Published:2022-12-01
Contact: Chen Liwei E-mail:iron9999@126.com
Supported by:
National Key Research and Development Program(2018YFC1707400)

摘要/Abstract

摘要：

三阴性乳腺癌为侵袭性乳腺癌的一种亚型，约占所有乳腺癌的15%，其临床治疗较为棘手，易复发转移，中位生存期短，预后较差。戈沙妥珠单抗是全球首个获批的靶向滋养细胞表面抗原2的抗体偶联药物，其临床疗效显著，安全性高，不良反应较小，给三阴性乳腺癌的治疗带来了新的希望。

关键词: 三阴性乳腺癌, 临床研究, 戈沙妥珠单抗

Abstract:

Triple-negative breast cancer is a subtype of invasive breast cancer， accounting for about 15% of all breast cancers. Its clinical treatment is relatively difficult， prone to recurrence and metastasis， with a short median survival and poor prognosis. Sacituzumab govitecan is the first approved antigen-coupled drug targeting trophoblast surface antigen 2 in the world. It has significant clinical efficacy， high safety and less adverse reactions， which brings new hope to the treatment of triple-negative breast cancer.

Key words: Triple negative breast neoplasms, Clinical study, Sacituzumab govitecan

王孟超, 陈立伟, 孔凡铭. 戈沙妥珠单抗治疗三阴性乳腺癌的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 619-622.

Wang Mengchao, Chen Liwei, Kong Fanming. Progress in the treatment of triple negative breast cancer with sacituzumab govitecan[J]. Journal of International Oncology, 2022, 49(10): 619-622.

参考文献 32

[1]	王佳荔. 分子分型与基因组分析推动难治性转移性三阴性乳腺癌的精准治疗: FUTURE试验[J]. 国际肿瘤学杂志, 2021, 48(11): 698-701. DOI: 10.3760/cma.j.cn371439-20210429-00138. doi: 10.3760/cma.j.cn371439-20210429-00138
[2]	Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress[J]. Breast Cancer Res, 2020, 22(1): 61. DOI: 10.1186/s13058-020-01296-5. doi: 10.1186/s13058-020-01296-5 pmid: 32517735
[3]	Tung N, Garber JE. PARP inhibition in breast cancer: progress made and future hopes[J]. NPJ Breast Cancer, 2022, 8(1): 47. DOI: 10.1038/s41523-022-00411-3. doi: 10.1038/s41523-022-00411-3 pmid: 35396508
[4]	Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. doi: 10.1016/S0140-6736(20)32531-9 pmid: 33278935
[5]	张喆, 贾立周, 唐奇, 等. TROP2和VEGFR2在三阴性乳腺癌中的表达及与临床病理因素的相关性研究[J]. 南京医科大学学报(自然科学版), 2019, 39(10): 1453-1458, 1471. DOI: 10.7655/NYDXBNS20191009. doi: 10.7655/NYDXBNS20191009
[6]	U.S. Food & Drug. FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer[EB/OL]. [2021-04-08] [2022-09-22]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-sacituzumab-govitecan-triple-negative-breast-cancer.
[7]	孙正魁, 江泽飞. 2022版《中国临床肿瘤学会乳腺癌诊疗指南》更新解读[J]. 中国肿瘤外科杂志, 2022, 14(3): 212-218. DOI: 10.3969/j.issn.1674-4136.2022.03.002. doi: 10.3969/j.issn.1674-4136.2022.03.002
[8]	国家药品监督管理局. 2022年6月10日药品批准证明文件待领取信息发布[EB/OL]. [2022-06-10] [2022-09-06]. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20220610083017154.html.
[9]	云顶新耀. 云顶新耀与吉利德科学联合公布在中国转移性三阴性乳腺癌患者中开展的戈沙妥珠单抗2b期研究达到总体缓解率的主要终点[EB/OL]. [2021-11-11] [2022-09-06]. https://www.everestmedicines.com/CN/News_detail.aspx?nid=432.
[10]	Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019, 380(8): 741-751. DOI: 10.1056/NEJMoa1814213. doi: 10.1056/NEJMoa1814213
[11]	Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16): 1529-1541. DOI: 10.1056/NEJMoa2028485. doi: 10.1056/NEJMoa2028485
[12]	Bardia A, Hurvitz SA, Rugo HS, et al. A plain language summary of the ASCENT study: sacituzumab govitecan for metastatic triple-negative breast cancer[J]. Future Oncol, 2021, 17(30): 3911-3924. DOI: 10.2217/fon-2021-0868. doi: 10.2217/fon-2021-0868
[13]	Fleming PJ Jr, Karpio S, Lombardo N. Sacituzumab govitecan for treatment of refractory triple-negative metastatic breast cancer[J]. J Adv Pract Oncol, 2021, 12(7): 747-752. DOI: 10.6004/jadpro.2021.12.7.8. doi: 10.6004/jadpro.2021.12.7.8 pmid: 34671504
[14]	Rozenblit M, Lustberg MB. Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer[J]. Ann Transl Med, 2022, 10(7): 390. DOI: 10.21037/atm-22-484. doi: 10.21037/atm-22-484 pmid: 35530962
[15]	Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase Ⅲ ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer[J]. Ann Oncol, 2021, 32(9): 1148-1156. DOI: 10.1016/j.annonc.2021.06.002. doi: 10.1016/j.annonc.2021.06.002 pmid: 34116144
[16]	Pavone G, Motta L, Martorana F, et al. A new kid on the block: sacituzumab govitecan for the treatment of breast cancer and other solid tumors[J]. Molecules, 2021, 26(23): 7294. DOI: 10.3390/molecules26237294. doi: 10.3390/molecules26237294
[17]	O'Shaughnessy J, Brufsky A, Rugo HS, et al. 258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase Ⅲ ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC)[J]. Ann Oncol, 2021, 32(Supplement 5): S473-S474. DOI: 10.1016/j.annonc.2021.08.541. doi: 10.1016/j.annonc.2021.08.541
[18]	O'Shaughnessy J, Brufsky A, Rugo HS, et al. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer[J]. Breast Cancer Res Treat, 2022, 195(2): 127-139. DOI: 10.1007/s10549-022-06602-7. doi: 10.1007/s10549-022-06602-7
[19]	Olivier T, Prasad V. Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): four design features in the ASCENT trial potentially favored the experimental arm[J]. Transl Oncol, 2022, 15(1): 101248. DOI: 10.1016/j.tranon.2021.101248. doi: 10.1016/j.tranon.2021.101248
[20]	Rugo HS, Tolaney SM, Loirat D, et al. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer[J]. NPJ Breast Cancer, 2022, 8(1): 98. DOI: 10.1038/s41523-022-00467-1. doi: 10.1038/s41523-022-00467-1 pmid: 36038616
[21]	Loibl S, Loirat D, Tolaney SM, et al. 257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)[J]. Ann Oncol, 2021, 32(Supplement 5): S472-S473. DOI: 10.1016/j.annonc.2021.08.540. doi: 10.1016/j.annonc.2021.08.540
[22]	Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics[J]. Cancer, 2017, 123(19): 3843-3854. DOI: 10.1002/cncr.30789. doi: 10.1002/cncr.30789 pmid: 28558150
[23]	Drugs. com. Trodelvy[EB/OL]. [2022-06-01] [2022-09-06]. https://www.drugs.com/pro/trodelvy.html.
[24]	Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update[J]. J Clin Oncol, 2020, 38(24): 2782-2797. DOI: 10.1200/JCO.20.01296. doi: 10.1200/JCO.20.01296 pmid: 32658626
[25]	Spring LM, Nakajima E, Hutchinson J, et al. Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities[J]. Oncologist, 2021, 26(10): 827-834. DOI: 10.1002/onco.13878. doi: 10.1002/onco.13878
[26]	Spring L, Tolaney SM, Desai NV, et al. Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: results from the NeoSTAR trial[J]. J Clin Oncol, 2022, 40(16_suppl): 512. DOI: 10.1200/JCO.2022.40.16_suppl.512. doi: 10.1200/JCO.2022.40.16_suppl.512
[27]	Rugo HS, Bardia A, Marmé F, et al. Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR⁺/HER2^-) advanced breast cancer[J]. J Clin Oncol, 2022, 40(17_suppl): LBA1001. DOI: 10.1200/JCO.2022.40.17_suppl.LBA1001. doi: 10.1200/JCO.2022.40.17_suppl.LBA1001
[28]	ClinicalTrials.gov. Sacituzumab govitecan in primary HER2-negative breast cancer (SASCIA)[EB/OL]. [2022-04-20] [2022-09-06]. https://clinicaltrials.gov/ct2/show/record/NCT04595565.
[29]	ClinicalTrials.gov. A study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with metastatic or inoperable locally advanced triple-negative breast cancer (Morpheus-TNBC)[EB/OL]. [2022-10-18] [2022-09-06]. https://clinicaltrials.gov/ct2/show/record/NCT03424005.
[30]	ClinicalTrials.gov. Sacituzumab govitecan +/- pembrolizumab in metastatic TNBC[EB/OL]. [2022-03-16] [2022-09-06]. https://clinicaltrials.gov/ct2/show/NCT04468061.
[31]	ClinicalTrials.gov. Study to evaluate sacituzumab govitecan in combination with talazoparib in patients with metastatic breast cancer[EB/OL]. [2021-10-27] [2022-09-06]. https://www.clinicaltrials.gov/ct2/show/NCT04039230.
[32]	Coates JT, Sun S, Leshchiner I, et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer[J]. Cancer Discov, 2021, 11(10): 2436-2445. DOI: 10.1158/2159-8290.CD-21-0702. doi: 10.1158/2159-8290.CD-21-0702 pmid: 34404686

戈沙妥珠单抗治疗三阴性乳腺癌的研究进展

Progress in the treatment of triple negative breast cancer with sacituzumab govitecan

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 32

相关文章 10

编辑推荐

Metrics

本文评价

[1]	徐凡, 王婧, 毛宁, 王世雄, 李金茂. 戈沙妥珠单抗治疗晚期三阴性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 508-510.
[2]	潘书兰, 刘畅, 贺平. 福瑞替尼对三阴性乳腺癌血管生成、肿瘤生长及IRE1-ASK1-JNK通路的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 457-462.
[3]	李彬, 张桂芳, 周林静, 杨小冬, 何秋立, 贾思思, 黄普超, 梁嘉欣. 三阴性乳腺癌中PIK3CA基因状态与临床特征及预后的关系[J]. 国际肿瘤学杂志, 2023, 50(5): 263-267.
[4]	谢露露, 丁江华. 免疫治疗在晚期三阴性乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(11): 672-676.
[5]	吴家宜, 陈柯羽, 邵喜英, 王晓稼. CDK4/6抑制剂通过调控三阴性乳腺癌免疫微环境促进抗肿瘤免疫的机制研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 362-365.
[6]	牛瑞琪, 刘萍萍, 杜瀛瀛. 早期非小细胞肺癌术后微小残留病灶检测技术与应用进展[J]. 国际肿瘤学杂志, 2022, 49(10): 623-626.
[7]	王佳荔. 分子分型与基因组分析推动难治性转移性三阴性乳腺癌的精准治疗:FUTURE试验[J]. 国际肿瘤学杂志, 2021, 48(11): 698-701.
[8]	李开春, 王雅杰. 转移性三阴性乳腺癌临床研究现状[J]. 国际肿瘤学杂志, 2020, 47(3): 169-173.
[9]	亢野,李建一,杨向红. 三阴性乳腺癌干细胞研究进展[J]. 国际肿瘤学杂志, 2019, 46(6): 362-365.
[10]	孙娜, 杨文燕. 洛铂治疗肿瘤的研究进展[J]. 国际肿瘤学杂志, 2012, 39(12): 907-909.